Zoetis Inc.
0M3Q.L
London Stock Exchange76.12
USD
-0.16
- -
Zoetis Inc.
0M3Q.L
(London Stock Exchange)
Recent
price
76.12
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Zoetis Inc. discovers, develops, manufactures and commercializes animal health medicines, vaccines, diagnostics, biodevices, genetic tests, precision livestock farming technologies and other services for companion animals including dogs, cats and horses, as well as livestock such as cattle, swine, poultry, fish and sheep; core product categories encompass parasiticides like Simparica Trio and Advocate; vaccines for disease prevention; dermatology treatments; anti-infectives; pain management and sedation solutions including monoclonal antibodies such as Cytopoint, Librela and Solensia for allergic dermatitis and osteoarthritis; other pharmaceuticals; and diagnostics comprising point-of-care tests, reference laboratory services and blood glucose monitors. The company, originally established in 1952 as a Pfizer animal health division and spun off as an independent entity in 2013, maintains global operations across more than 100 countries with primary markets among veterinarians, livestock producers and pet owners; it is headquartered in Parsippany, New Jersey. Recent strategic developments include the sale of its medicated feed additives portfolio and certain water-soluble products to Phibro Animal Health Corporation, completed in November 2024 for $350 million to sharpen focus on higher-growth areas like vaccines, biologics and genetics; the acquisition of Veterinary Pathology Group on November 11, 2025, to bolster veterinary diagnostics capabilities; collaboration with Blacksmith Medicines Inc. for novel antibiotics; European approval of Portela, a long-acting monoclonal antibody for feline osteoarthritis pain with a 2026 launch; and pipeline advancement in chronic kidney disease, oncology, cardiology, anxiety and metabolic disorders like diabetes and obesity, targeting over $5 billion in addressable markets.